Browsing Tag
Hematology
24 posts
Does Priority Review signal a commercial breakthrough for Protagonist Therapeutics, Inc.?
Takeda and Protagonist secure FDA Priority Review for rusfertide in PV. Explore the strategic, financial, and competitive implications now.
Myelofibrosis breakthrough? Incyte’s INCA033989 delivers clinical and molecular wins
Incyte’s mutCALR antibody shows promise in myelofibrosis and ET. Find out what ASH 2025 data reveals about INCA033989’s future potential.
Gilead’s CAR T breakthrough: Yescarta delivers consistent results beyond transplant settings
Yescarta shows durable survival and response benefits in second-line large B-cell lymphoma across transplant-eligible and ineligible patients. Read the latest trial update.
Rigel Pharmaceuticals’ R289 delivers promising phase 1b results in transfusion-dependent MDS
Find out how Rigel Pharmaceuticals, Inc. is advancing R289 for lower-risk myelodysplastic syndrome with promising new phase 1b data—read the latest insights now!
Wall Street reacts as Johnson & Johnson circles Protagonist Therapeutics in a potential multibillion-dollar buyout
Explore how Johnson & Johnson’s bid to acquire Protagonist Therapeutics could reshape its immunology and hematology pipeline—details inside.
BeOne Medicines’ sonrotoclax trial hits primary endpoint in mantle cell lymphoma patients
BeOne Medicines’ sonrotoclax met its primary endpoint in mantle cell lymphoma, with positive Phase 1/2 trial results. Find out what this means for patients.
Sonic Healthcare USA expands oncology footprint with Cairo Diagnostics acquisition
Sonic Healthcare USA acquires Cairo Diagnostics to expand oncology diagnostics nationwide. Find out how this deal strengthens precision testing access.
Bristol Myers Squibb and 2seventy bio’s Abecma gets positive FDA committee vote for multiple myeloma
In a significant development in the healthcare industry, Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq:…
Novartis announces takeover bid for MorphoSys AG to boost oncology pipeline
In a significant move within the pharmaceutical industry, Novartis has entered into an agreement to launch a voluntary…
AstraZeneca to acquire Gracell Biotechnologies for $1.2bn to expand cell therapy capabilities
AstraZeneca has announced a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL) for an upfront cash…